A retrospective study suggested that irAEs with second-line nivolumab are associated with PFS and OS in patients with advanced NSCLC.
from Latest articles from Cancer Therapy Advisor Lung Cancer https://ift.tt/2OSq92b
from Latest articles from Cancer Therapy Advisor Lung Cancer https://ift.tt/2OSq92b